MedTrace Logo

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

NCT05814952 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-04-18

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and efficacy of LX103 treatment of X-linked retinoschisis. This study will enroll subjects aged ≥ 6 years old to receive a single unilateral intravitreal (IVT) injection of LX103 to evaluate its safety and efficacy.

Conditions

  • X-linked Retinoschisis

Interventions

GENETIC

LX103 Injection

Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.

Sponsors & Collaborators

  • Innostellar Biotherapeutics

    collaborator UNKNOWN

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2024-08-31
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05814952 on ClinicalTrials.gov